Trial of AST-201 for GPC3-positive advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must have an advanced solid tumor that has come back or spread, and that has been shown to have the GPC3 protein on it.
- You must be able to care for yourself (ECOG score 0 or 1).
- Your major organs like bone marrow, liver, kidneys, and heart must be working well enough.
- If you have liver cancer, your liver function must be grade A on the Child-Pugh scale.
- You must not have had any other cancer treatment within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, GSK5533524, alone or with other treatments, for people with advanced solid tumors that have stopped responding to standard therapies. It aims to find out if the drug is safe and shows early signs of working.
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This trial tests a custom immune-cell treatment (CAR-T) that targets a marker called GPC3 in people with advanced hepatocellular carcinoma (a type of liver cancer). It’s for cases where standard treatments have not worked well, and the goal is to shrink tumors and improve outcomes.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.